AllCells’ Clinical Grade Mobilized leukopaks are apheresis products collected from healthy donors treated with FDA-approved drugs to stimulate mobilization of CD34+ hematopoietic stem and progenitor cells from the bone marrow to the peripheral blood. This procedure results in large-scale yields of CD34+ cells. Peripheral blood is collected from IRB-consented donors using the continuous flow Spectra Optia® Apheresis System directly into ACD-A anticoagulant at AllCells’ FDA-registered, IRB-approved collection facilities.
Regimen details: Reg H = Filgrastim (Neupogen®) 10ug/kg/day x 5 days + Plerixafor (Mozobil®) 240ug/kg/day x 2 days on day 4 and 5 (evenings), apheresis on day 5 and 6.
Disclaimer: This product is available for further manipulation, not intended for human use. AllCells is in the process of obtaining FDA approval to use this product for further manipulation for the purpose of manufacturing treatment and/or drugs intended for human use.
Donors with the right attributes are a critical part of any cell therapy program. AllCells Donor Management Services can help you find, screen and retain donors from our repository comprised of highly-characterized, HLA-typed donors with diverse demographics and clinical parameters that can meet program-specific criteria from research and development to commercialization.
Learn More